Topical nano-liposomal Amphotericin B 0.4% (SinaAmpholeish) twice a day for 28 days

2 trials

Sponsors

National Institute for Medical Research Development (NIMAD)

Conditions

Cutaneous Leishmaniasis. Cutaneous leishmaniasis

Phase 3

safety and efficacy comparison trial of topical nano-liposomal form of Amphotericin B with national standard treatment for cutaneous leishmaniasis caused by Leishmania major (Phase 3)

Active, not recruitingIRCT201612101475N11

National Institute for Medical Research Development (NIMAD)Cutaneous Leishmaniasis. Cutaneous leishmaniasis

Start: 2016-12-15Target: 150Updated: 2018-02-22

?Efficacy of heat therapy ?plus topical liposomal Amphotericin B for the treatment of ? cutaneous leishmaniasis caused by ?Leishmania major

Active, not recruitingIRCT201510031475N8

National Institute for Medical Research Development (NIMAD)Cutaneous Leishmaniasis. Cutaneous leishmaniasis

Start: 2016-12-15Target: 150Updated: 2018-02-22